We provide you with 20 years of free, institutional-grade data for CRTX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CRTX. Explore the full financial landscape of CRTX stock.
| Reported Date | CIK | Ticker | Type |
|---|
Cortexyme, Inc(NASDAQ:CRTX) 
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase I...
Website: http://www.cortexyme.com
Founded: 2012
Full Time Employees: 37 (May 2021)
CEO: Casey Crawford Lynch
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about CRTX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.